Evogene

Evogene is a life sciences technology company revolutionizing product development in the pharmaceutical and agricultural industries through cutting-edge computational biology, computational chemistry, and generative AI. The company bridges the gap between the commercial product needs of pharma and ag-chemical industries and specifically tailored computational innovation, with the goal of translating generative AI discoveries into practical, commercially viable products.

At the heart of Evogene's approach is the recognition that over 90% of small molecules fail to reach the commercial phase — a challenge that demands a disruptive solution. Evogene addresses this through its proprietary AI-first technology platform, enabling the design of novel small molecules optimized across multiple critical parameters to increase the probability of success while reducing time and costs.

Core Technology: ChemPass AI™

• ChemPass AI™ is Evogene's proprietary generative AI tech-engine, purpose-built for optimized multi-parameter novel small molecule design.
• The platform creates highly potent, unique small molecules by simultaneously optimizing across multiple critical parameters relevant to both drug discovery and agricultural chemical development.
• ChemPass AI™ is designed to increase the probability of commercial success while significantly reducing development time and costs.
• The platform supports both in-house product development and strategic partnerships, enabling a flexible and scalable business model.

Pharma Division: Drug Discovery

• Evogene applies its AI-driven molecule design capabilities to increase the probability of success for novel therapeutics in pharmaceutical drug discovery.
• The company has partnered with Unravel Biosciences to design optimized therapeutic candidates aimed at promoting remyelination for multiple sclerosis and other neurodegenerative disorders, combining ChemPass AI with Unravel's patient RNA-derived Living Molecular Twins™ technology.
• A collaboration with Systasy Bioscience, supported by EUREKA funding, focuses on extending the PathwayProfiler platform to neutrophil biology, targeting hyper-inflammatory diseases in partnership with LMU and the Weizmann Institute.
• Evogene has partnered with Queensland University of Technology to leverage AI-driven technology for accelerating a path from research to real-world translational outcomes in cell and molecular biology.
• A collaboration with Professor Ehud Gazit, a world leader in molecular self-assembly, integrates fundamental understanding of how small metabolites self-assemble into amyloid-like structures with Evogene's AI-driven drug design platform to develop novel therapeutics targeting pathological processes in rare and common diseases.

Agriculture Division: Ag Chemicals and Crop Protection

• Evogene applies its computational chemistry and generative AI capabilities to the development of next-generation crop protection solutions, with a focus on sustainable agriculture.
• The company operates AgPlenus as a subsidiary focused on agricultural chemicals, with proven results in identifying novel herbicide chemistry targeting new modes of action for weed control — an area the industry has lacked for decades.
• AgPlenus has collaborated with Bayer's Crop Science division, with the partnership recognized for accelerating the delivery of sustainable and affordable crop protection solutions and setting a new benchmark in the industry.
• Another Evogene subsidiary, Casterra, has announced successful commercial field trials in Brazil, positioning castor oil as a promising candidate for economically viable biofuel feedstock.

Strategic Partnerships and Collaborations

• Evogene has an expanded collaboration with Google Cloud Israel, leveraging advanced AI agents to automate and scale complex discovery workflows, accelerating the speed and precision of small molecule identification.
• The company's flexible business model enables collaboration through strategic partnerships or in-house expertise, facilitating the development of market-ready products across both drug discovery and agricultural chemicals.
• Evogene participates in industry events such as BIO-Europe Spring 2026, where it presents its pharma discovery achievements to the broader life sciences community.

Evogene's combination of proprietary generative AI technology, a growing portfolio of strategic partnerships across pharma and agriculture, and a flexible commercialization model positions it as a leader in next-generation molecular design for industries where innovation speed and commercial viability are critical.